Related Experiment Video
Updated: Feb 4, 2026

Chronic Constriction of the Sciatic Nerve and Pain Hypersensitivity Testing in Rats
Published on: March 13, 2012
SIRT1 Facilitates Beclin-1 Nuclear Translocation to Mitigate Nociceptive Hypersensitivity in Rats with Bone Cancer
Qiuli He1, Wenjie Li2, Cuie Deng3
1Department of Anesthesiology and Pain Research Center, Jiaxing University Affiliated Hospital, The First Hospital of Jiaxing, Jiaxing, Zhejiang Province, China.
Background:
The etiology of bone cancer pain (BCP) is multifaceted, and effective therapeutic strategies for treating the condition remain elusive. Prior research has implicated sirtuin 1 (SIRT1) in the pathogenesis of BCP, suggesting the protein's potential to modulate autophagy and mitigate nociceptive sensitization; however, the underlying mechanisms of BCP are not fully understood.
Objectives:
This study aimed to elucidate the role of SIRT1 in activating autophagy and its impact on the development of nociceptive hypersensitivity in a rat model of BCP.
Study Design:
Controlled animal study.
Setting:
Female Sprague Dawley® rats weighing 180-220 g were used.
Methods:
The BCP model was established by a single injection of Walker 256 breast cancer cells (10 µL, 107cells/mL) into the tibia. Mechanical pain sensitivity was assessed behaviorally using an Electronic von Frey Anesthesiometer.
Results:
Western blot (WB) analysis revealed reduced SIRT1 levels and elevated beclin-1 expression, an increased LC3II/LC3I ratio, and enhanced P62 expression in the dorsal horns of spinal cord tissues from rats with BCP. Immunofluorescence assays demonstrated co-localization of SIRT1 with neuronal cells and beclin-1. Subsequent experiments indicated that intrathecal administration of a SIRT1 agonist in rats with BCP postponed the downregulation of SIRT1, decreased the acetylation of beclin-1, and facilitated beclin-1 nuclear translocation. This treatment also led to a reduction in the LC3II/LC3I ratio and P62 expression levels. Collectively, these findings suggest that SIRT1 may ameliorate nociceptive hypersensitivity in rats with BCP through the promotion of beclin-1 nuclear translocation, thereby restoring autophagic flux..
Limitations:
This study focused on peripheral/spinal mechanisms but not supraspinal/cortical contributions. Pharmacological tests were limited to a single time point, potentially missing dynamic pain changes during tumor progression. Nevertheless, the findings of this study offer valuable preliminary insights.
Conclusion:
This research uncovers a novel mechanism of SIRT1 in the genesis of nociceptive hypersensitivity in BCP and offers potential avenues for therapeutic intervention.
Insights
Sirtuin 1 (SIRT1) activation in rats with bone cancer pain (BCP) may reduce hypersensitivity by promoting autophagy. This study reveals a novel SIRT1 mechanism in BCP pain, offering therapeutic potential.
Area of Science:
- Neuroscience
- Oncology
- Molecular Biology
Background:
- Bone cancer pain (BCP) etiology is complex, with limited effective treatments.
- Sirtuin 1 (SIRT1) is implicated in BCP pathogenesis, potentially modulating autophagy and pain sensitization.
- The precise mechanisms underlying BCP remain incompletely understood.
Purpose of the Study:
- To investigate the role of SIRT1 in autophagy activation.
- To determine SIRT1's impact on nociceptive hypersensitivity in a rat BCP model.
Main Methods:
- A rat model of BCP was established using Walker 256 breast cancer cells injected into the tibia.
- Mechanical pain sensitivity was assessed using an Electronic von Frey Anesthesiometer.
- Western blot and immunofluorescence assays analyzed SIRT1, beclin-1, LC3II/LC3I ratio, and P62 expression.
Main Results:
- BCP rats exhibited reduced SIRT1 and increased beclin-1, LC3II/LC3I ratio, and P62 expression in spinal cord dorsal horns.
- SIRT1 agonist treatment in BCP rats delayed SIRT1 downregulation, decreased beclin-1 acetylation, and promoted beclin-1 nuclear translocation.
- SIRT1 activation reduced the LC3II/LC3I ratio and P62 levels, suggesting restored autophagic flux and ameliorated nociceptive hypersensitivity.
Conclusions:
- SIRT1 activation may alleviate BCP-induced nociceptive hypersensitivity via enhanced autophagy and beclin-1 nuclear translocation.
- This study identifies a novel SIRT1-mediated mechanism in BCP pain.
- Findings suggest potential therapeutic strategies targeting SIRT1 for BCP management.
Related Concept Videos
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Nociception
Restorative Care
Facilitated Transport
Social Facilitation
Nuclear Stability
To hold positively charged protons together...

